Morgan Stanley lowered the firm’s price target on GSK (GSK) to 1,290 GBp from 1,355 GBp and keeps an Underweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK’s Promising Phase 2 Study on IPF Drug GSK3915393: Market Implications
- GlaxoSmithKline Downgraded to Sell Amid Blenrep Sales Decline and Earnings Adjustments
- GSK price target lowered to 1,290 GBp from 1,355 GBp at Morgan Stanley
- GSK’s Long-term Study on CAB LA for HIV Prevention: Key Insights for Investors
- GSK’s New COPD Drug Study: What Investors Need to Know